222 related articles for article (PubMed ID: 11859905)
1. Cost savings in migraine associated with less chest pain on new triptan therapy.
Wang JT; Barr CE; Torigoe Y; Wang E; Rowland CR; Goldfarb SD
Am J Manag Care; 2002 Feb; 8(3 Suppl):S102-7. PubMed ID: 11859905
[TBL] [Abstract][Full Text] [Related]
2. Almotriptan versus sumatriptan in migraine treatment: direct medical costs of managing adverse chest symptoms.
Mannix LK; Adelman JU; Goldfarb SD; Von S; Kozma CM
Am J Manag Care; 2002 Feb; 8(3 Suppl):S94-101. PubMed ID: 11859910
[TBL] [Abstract][Full Text] [Related]
3. Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan.
Wang JT; Barr CE; Goldfarb SD
Headache; 2002 Jan; 42 Suppl 1():38-43. PubMed ID: 11966863
[TBL] [Abstract][Full Text] [Related]
4. Health outcomes evaluations: estimating the impact of almotriptan in managed care settings.
Mayo KW; Osterhaus JT
Am J Manag Care; 2002 Feb; 8(3 Suppl):S85-93. PubMed ID: 11859909
[TBL] [Abstract][Full Text] [Related]
5. [Management costs of chest and CNS-related adverse events associated with the treatment of acute migraine attacks with oral triptans].
Slof J; Badia X; Lainez-Andres JM; Galvan J; Heras J
Neurologia; 2005; 20(6):290-8. PubMed ID: 16007512
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous sumatriptan compared with usual acute treatments for migraine: clinical and pharmacoeconomic evaluation.
Laloux P; Vakaet A; Monseu G; Jacquy J; Bourgeois P; van der Linden C
Acta Neurol Belg; 1998 Dec; 98(4):332-41. PubMed ID: 9922821
[TBL] [Abstract][Full Text] [Related]
7. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.
Mullins CD; Subedi PR; Healey PJ; Sanchez RJ
Pharmacotherapy; 2007 Aug; 27(8):1092-101. PubMed ID: 17655509
[TBL] [Abstract][Full Text] [Related]
8. Almotriptan improves response rates when treatment is within 1 hour of migraine onset.
Dowson AJ; Massiou H; Lainez JM; Cabarrocas X
Headache; 2004 Apr; 44(4):318-22. PubMed ID: 15109355
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic, and clinical consequences.
Cohen JA; Beall DG; Miller DW; Beck A; Pait G; Clements BD
Fam Med; 1996 Mar; 28(3):171-7. PubMed ID: 8900548
[TBL] [Abstract][Full Text] [Related]
10. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.
Diener HC; Gendolla A; Gebert I; Beneke M
Headache; 2005; 45(7):874-82. PubMed ID: 15985104
[TBL] [Abstract][Full Text] [Related]
11. Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes.
Cohen JA; Beall D; Beck A; Rawlings J; Miller DW; Clements B; Pait DG; Batenhorst A
Clin Ther; 1999 Jan; 21(1):190-204. PubMed ID: 10090435
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.
Diener HC
Curr Med Res Opin; 2005 Oct; 21(10):1603-10. PubMed ID: 16238900
[TBL] [Abstract][Full Text] [Related]
13. Almotriptan: a review of pharmacology, clinical efficacy, and tolerability.
Von S
Am J Manag Care; 2002 Feb; 8(3 Suppl):S74-9. PubMed ID: 11859907
[TBL] [Abstract][Full Text] [Related]
14. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS
Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814
[TBL] [Abstract][Full Text] [Related]
15. The comparative clinical and economic benefits of drugs should be established and discussed as part of any formulary decision process.
Richardson MS; Bowers BW; Petrie JL
Am J Manag Care; 2002 Aug; 8(8):693-4; author reply 694-5. PubMed ID: 12212757
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness of sumatriptan in a managed care population.
Legg RF; Sclar DA; Nemec NL; Tarnai J; Mackowiak JI
Am J Manag Care; 1997 Jan; 3(1):117-22. PubMed ID: 10169243
[TBL] [Abstract][Full Text] [Related]
17. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population.
Sheftell FD; Feleppa M; Tepper SJ; Volcy M; Rapoport AM; Bigal ME
Headache; 2004; 44(7):661-8. PubMed ID: 15209687
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain--results of a model-based meta-analysis that accounts for encapsulation.
Mandema JW; Cox E; Alderman J
Cephalalgia; 2005 Sep; 25(9):715-25. PubMed ID: 16109054
[TBL] [Abstract][Full Text] [Related]
19. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
[TBL] [Abstract][Full Text] [Related]
20. [New triptanes in control of migraine attacks. More rapid onset of action--more efficient reduction of pain].
MMW Fortschr Med; 2002 Jan; 144(3-4):52-3. PubMed ID: 11862794
[No Abstract] [Full Text] [Related]
[Next] [New Search]
